Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities:
Net earnings	$ 352.5	$ 696.0	$ 480.0
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization	2,109.9	1,805.8	1,523.0
Deferred income tax benefit	(264.3)	(111.4)	(609.5)
Litigation settlements and other contingencies, net	(31.6)	(40.1)	597.7
Unrealized losses on acquisition-related foreign currency derivatives	0.0	0.0	128.6
Loss from equity method investments	78.7	58.0	112.8
Stock-based compensation expense	(3.3)	74.7	88.9
Write off of financing fees	2.7	3.2	35.8
Other non-cash items	286.1	261.0	499.4
Changes in operating assets and liabilities:
Accounts receivable	340.1	(162.2)	(131.8)
Inventories	(547.6)	(129.5)	(279.3)
Trade accounts payable	220.3	14.4	87.7
Income taxes	(23.9)	15.2	37.5
Other operating assets and liabilities, net	(177.9)	(420.3)	(523.6)
Net cash provided by operating activities	2,341.7	2,064.8	2,047.2
Cash flows from investing activities:
Cash paid for acquisitions, net	(65.9)	(167.0)	(6,481.9)
Capital expenditures	(252.1)	(275.9)	(390.4)
Payments for product rights and other, net	(943.5)	(620.3)	(360.2)
Cash paid for Meda's unconditional deferred payment	0.0	0.0	(308.0)
Settlement of acquisition-related foreign currency derivatives	0.0	0.0	(128.6)
Proceeds from sale of assets and subsidiaries	29.3	86.7	0.0
Purchase of marketable securities	(63.4)	(96.5)	(30.2)
Proceeds from sale of marketable securities	85.2	96.6	21.5
Net cash used in investing activities	(1,210.4)	(976.4)	(7,677.8)
Cash flows from financing activities:
Proceeds from issuance of long-term debt	2,577.9	876.1	11,752.2
Payment of long-term debt	(3,165.2)	(2,232.7)	(6,296.3)
Payment of financing fees	(21.4)	(10.1)	(112.6)
Change in short-term borrowings, net	(44.4)	(2.9)	40.8
Purchase of common stock	(432.0)	(500.2)	0.0
Proceeds from exercise of stock options	17.8	17.8	13.8
Taxes paid related to net share settlement of equity awards	(10.1)	(7.4)	(17.5)
Contingent consideration payments	(11.9)	(26.1)	(35.5)
Acquisition of noncontrolling interest	(0.6)	(7.5)	(1.1)
Other items, net	(1.0)	(0.1)	0.8
Net cash (used in) provided by financing activities	(1,090.9)	(1,893.1)	5,344.6
Effect on cash of changes in exchange rates	(21.0)	27.6	(9.6)
Net increase (decrease) in cash, cash equivalents and restricted cash	19.4	(777.1)	(295.6)
Cash, cash equivalents and restricted cash — beginning of period	369.9	1,147.0	1,442.6
Cash, cash equivalents and restricted cash — end of period	389.3	369.9	1,147.0
Non-cash transactions:
Contingent consideration		4.0	16.0
Ordinary shares issued for acquisition	0.0	0.0	1,281.7
Cash paid during the period for:
Income taxes	228.6	285.7	285.6
Interest	460.8	474.0	357.2
Other current liabilities
Non-cash transactions:
Contingent consideration	0.0	4.0	16.0
Retained Earnings [Member]
Cash flows from operating activities:
Net earnings	$ 352.5	$ 696.0	$ 480.0